|
🐜
|
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
20 auth.
W. Wick,
C. Hartmann,
C. Engel,
M. Stoffels,
J. Felsberg,
F. Stockhammer,
M. Sabel,
S. Koeppen,
R. Ketter,
R. Meyermann,
...
M. Rapp,
C. Meisner,
R. Kortmann,
T. Pietsch,
O. Wiestler,
U. Ernemann,
M. Bamberg,
G. Reifenberger,
A. von Deimling,
M. Weller
|
9 |
2009 |
9
🐜
|
|
🐜
|
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
48 auth.
U. Herrlinger,
T. Tzaridis,
F. Mack,
J. Steinbach,
U. Schlegel,
M. Sabel,
P. Hau,
R. Kortmann,
D. Krex,
O. Grauer,
R. Goldbrunner,
O. Schnell,
O. Bähr,
M. Uhl,
C. Seidel,
...
G. Tabatabai,
T. Kowalski,
F. Ringel,
F. Schmidt-Graf,
B. Suchorska,
S. Brehmer,
A. Weyerbrock,
M. Renovanz,
L. Bullinger,
N. Galldiks,
P. Vajkoczy,
M. Misch,
H. Vatter,
M. Stuplich,
N. Schäfer,
S. Kebir,
J. Weller,
C. Schaub,
W. Stummer,
J. Tonn,
M. Simon,
V. Keil,
M. Nelles,
H. Urbach,
M. Coenen,
W. Wick,
M. Weller,
R. Fimmers,
M. Schmid,
E. Hattingen,
T. Pietsch,
C. Coch,
M. Glas
|
8 |
2019 |
8
🐜
|
|
🐜
|
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
28 auth.
M. Weller,
G. Tabatabai,
B. Kästner,
J. Felsberg,
J. Steinbach,
A. Wick,
O. Schnell,
P. Hau,
U. Herrlinger,
M. Sabel,
H. Wirsching,
R. Ketter,
O. Bähr,
M. Plattén,
J. Tonn,
...
U. Schlegel,
C. Marosi,
R. Goldbrunner,
R. Stupp,
K. Homicsko,
J. Pichler,
G. Nikkhah,
J. Meixensberger,
P. Vajkoczy,
S. Kollias,
J. Hüsing,
G. Reifenberger,
W. Wick
|
8 |
2015 |
8
🐜
|
|
🐜
|
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
13 auth.
J. Felsberg,
N. Thon,
S. Eigenbrod,
B. Hentschel,
M. Sabel,
M. Westphal,
G. Schackert,
F. Kreth,
T. Pietsch,
M. Löffler,
...
M. Weller,
G. Reifenberger,
J. Tonn
|
8 |
2011 |
8
🐜
|
|
🐜
|
Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas
10 auth.
F. Floeth,
M. Sabel,
C. Ewelt,
W. Stummer,
J. Felsberg,
G. Reifenberger,
...
H. Steiger,
G. Stoffels,
H. Coenen,
K. Langen
|
8 |
2011 |
8
🐜
|
|
🐜
|
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
19 auth.
W. Wick,
C. Meisner,
B. Hentschel,
M. Plattén,
A. Schilling,
B. Wiestler,
M. Sabel,
S. Koeppen,
R. Ketter,
M. Weiler,
...
G. Tabatabai,
A. von Deimling,
D. Gramatzki,
M. Westphal,
G. Schackert,
M. Loeffler,
M. Simon,
G. Reifenberger,
M. Weller
|
7 |
2013 |
7
🐜
|
|
🐜
|
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
24 auth.
W. Wick,
P. Roth,
C. Hartmann,
P. Hau,
Makoto Nakamura,
F. Stockhammer,
M. Sabel,
A. Wick,
S. Koeppen,
R. Ketter,
...
P. Vajkoczy,
I. Eyupoglu,
R. Kalff,
T. Pietsch,
C. Happold,
N. Galldiks,
F. Schmidt-Graf,
M. Bamberg,
G. Reifenberger,
M. Plattén,
A. von Deimling,
C. Meisner,
B. Wiestler,
M. Weller
|
7 |
2015 |
7
🐜
|
|
🐜
|
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
14 auth.
B. Suchorska,
M. Weller,
G. Tabatabai,
C. Senft,
P. Hau,
M. Sabel,
U. Herrlinger,
R. Ketter,
U. Schlegel,
C. Marosi,
...
G. Reifenberger,
W. Wick,
J. Tonn,
H. Wirsching
|
7 |
2015 |
7
🐜
|
|
🐜
|
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.
25 auth.
Verena Körber,
Jing Yang,
P. Barah,
Yonghe Wu,
D. Stichel,
Z. Gu,
M. Fletcher,
David T. W. Jones,
B. Hentschel,
K. Lamszus,
J. Tonn,
G. Schackert,
M. Sabel,
J. Felsberg,
A. Zacher,
...
K. Kaulich,
Daniel Hübschmann,
C. Herold‐Mende,
A. von Deimling,
M. Weller,
B. Radlwimmer,
M. Schlesner,
G. Reifenberger,
T. Höfer,
P. Lichter
|
7 |
2019 |
7
🐜
|
|
🐢
|
Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
10 auth.
J. Felsberg,
M. Rapp,
S. Loeser,
R. Fimmers,
W. Stummer,
M. Goeppert,
...
H. Steiger,
Britta Friedensdorf,
G. Reifenberger,
M. Sabel
|
7 |
2009 |
7
🐢
|
|
🐜
|
Finding the anaplastic focus in diffuse gliomas: The value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence
8 auth.
C. Ewelt,
F. Floeth,
J. Felsberg,
H. Steiger,
M. Sabel,
K. Langen,
...
G. Stoffels,
W. Stummer
|
7 |
2011 |
7
🐜
|
